Virax Biolabs Group Limited - Ordinary Shares (VRAX)
0.5291
-0.1005 (-15.96%)
NASDAQ · Last Trade: Dec 8th, 6:16 PM EST
Detailed Quote
Previous Close
0.6296
Open
0.6200
Bid
0.5200
Ask
0.5495
Day's Range
0.5210 - 0.6234
52 Week Range
0.3500 - 3.200
Volume
1,414,069
Market Cap
8.23M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
15,182,594
Chart
About Virax Biolabs Group Limited - Ordinary Shares (VRAX)
Virax Biolabs Group Limited is a biotechnology company focused on developing and commercializing innovative diagnostic solutions and therapeutics for viral infections, particularly in the fields of healthcare and disease prevention. The company leverages advanced technologies to create accurate diagnostic kits that aim to identify various viral pathogens, thereby aiding in effective disease management and treatment strategies. Virax is committed to enhancing global health outcomes by providing accessible and reliable testing solutions, which play a critical role in the early detection and monitoring of viral diseases. Read More
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Scienjoy Holding Corporation (NASDAQ: SJ) is emerging as one of the most intriguing deep-value opportunities in global small-cap tech. Powered by a cash-rich, high-margin China livestreaming business and a bold expansion into Dubai’s fast-developing metaverse and AI economy, the company offers investors something rare: a profitable core plus a “free option” on one of the world’s most ambitious new digital markets . For investors seeking asymmetric upside, real operational discipline, and underappreciated catalysts, Scienjoy stands at a compelling inflection point.
Get a pulse on the US markets on Wednesday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.
Virax Biolabs supports HHS's focus on vaccine efficacy transparency, offering technology to assess immune responses and collaborate with developers to improve vaccine research.
Virax Biolabs partners with Europa Biosite to distribute ImmuneSelect for research use, focusing on T-cell immunity and post-viral syndromes, including Long COVID.
Investors in healthcare and biotech sectors should keep an eye on several prominent companies making strides in innovation, clinical trials, and global expansion. Modular Medical (NASDAQ: MODD), Cardiol Therapeutics (NASDAQ: CRDL) , DBV Technologies (NASDAQ: DBVT) , and Virax Biolabs (NASDAQ: VRAX) are key players to watch in the ever-evolving medical landscape. Each company has announced significant developments in technology, trials, and product distribution, solidifying their positions in the market.
